Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005018 · ClinicalTrials.gov registry record · Phase 4
Safety and Effectiveness of a Combination Anti-HIV Drug Treatment
A Phase 4 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 4
- Development phase
- 150
- Enrollment target
NCT00005018: Completed Phase 4 study, sponsored by Glaxo Wellcome.
NCT00005018 is a Phase 4 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 150 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005018, a Phase 4 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 150 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir \[ABC\] plus efavirenz \[EFV\] plus didanosine \[ddI\]) with and without hydroxyurea (HU).
Interventions
- DRUG Hydroxyurea
- DRUG Efavirenz
- DRUG Didanosine
- DRUG Abacavir sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 1999-07 |
| Est. Completion | 2000-10 |
| Phase | Phase 4 |
What the finished NCT00005018 record still lists
NCT00005018 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (71% lower).
The record links to 0 conditions, and to 4 interventions - of which Hydroxyurea is the first listed.
NCT00005018 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005018 about?
NCT00005018 is a clinical study titled "Safety and Effectiveness of a Combination Anti-HIV Drug Treatment". The purpose of this study is to see if it is safe and effective to give HIV-positive patients a combination of anti-HIV drugs (abacavir \[ABC\] plus efavirenz \[EFV\] plus didanosine \[ddI\]) with and without hydroxyurea (HU).
What is the current status of trial NCT00005018?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 150 participants. The study started on 1999-07. Estimated completion is 2000-10.
What interventions are being tested in trial NCT00005018?
The interventions under investigation include: Hydroxyurea (DRUG), Efavirenz (DRUG), Didanosine (DRUG), Abacavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00005018?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00005018's enrollment target sits among peer trials
150 533rd of 2000 higher than 1,436 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia